COMPANY

Company Identity

LEADING GLOBAL R&D Innovator

CURACLE Co., Ltd. is introducing a new era, welcoming 150 years of happy and healthy life,
by developing global innovative new treatments for intractable diseases caused by aging and damaged blood vessels.

Embarking on a New Challenge, Miracle Cure, Leading Global Market

Open Healthy & Happy Living up to 150 years old

  • Present

    Unmet Medical Needs

    • Diabetic Retinopathy
    • Macular Degeneration
    • Ischemic Vascular Diseases
    • Diabetic Nephropathy
    • Cancer 
    • Non-alcoholic steatohepatitis (NASH)
    • Stroke 
    • Inflammatory Bowel Disease (IBD)

    Key Development

    Age-Related Vascular Diseases

    Intractable Metabolic Diseases

    Targeted Therapy / Immunotherapy for Cancer

    Present

    Creative Scientific Discovery

    Innovative Molecules

    New Clinical Concept

    • Vascular Normalization
    • Prevention of Aging
    • Restoration of Vascular Damage
    • Maintenance of Mitochondrial Function

    Novel Therapeutics
    Leading rapidly growing present and future market

Global growth by develoing unparalleled platform technology and creating innovative new drugs

Strengthening market leadership through the continued success of pipelines and global partnerships

  • Growth stage
    (2019-2020)

    • Portfolio consisting of drug candidates and early phase clinical trials
    • Completed Phase 2a clinical trial of CU01 & CU03
    • Entered Phase 1 clinical trial of CU06
    • Completed Series B financing
    • Build relationship with domestic and foreign partners
    • Completed technology assessment for special listings

  • Take-off Stage
    (2021-2023)

    • Add new innovative pipeline
    • Initial Public Offering (IPO)
    • Portfolio consisting of pre-clinical and late phase clinical trials
    • Out-licensing and co-development with domestic and international pharmaceutical companies
    • Creation of milestone profits
    • Establishment of second laboratory (toxicity & efficacy evaluation)
    • Addition of new innovative pipelines

  • Achieving VISION
    (2024-)

    • Establish unrivaled and innovative drug platform
    • Launch internally developed drugs worldwide
    • Global R&D innovator leader focused on unmet medical needs